SOUTH SAN FRANCISCO, Calif.--Axys Pharmaceuticals announced that it has signed an agreement with Wyeth-Ayerst Laboratories, a division of American Home Products, to conduct a clinical trial to study the role played by an Axys proprietary gene variant in drug metabolism. The polymorphism, identified in the cytochrome p450 3A4 gene, results from Axys's program to identify polymorphisms in drug metabolizing enzymes and is contained in Axys's exclusive GeneTrials database. The trial is designed to evaluate the effect of the polymorphism on the metabolism of two classes of marketed drugs to determine if patients who have the gene variant metabolize the drugs differently. Under terms of the agreement, Wyeth will conduct the clinical study and Axys will provide patient genotyping and intellectual property. Specific terms of the agreement were not disclosed.
Axys also announced a collaboration with Signal Pharma ceu ti cals for the accelerated discovery of compounds that interact with specific cell signaling pathways for which Signal has developed proprietary assays and with which it will screen small molecules derived from Axys's Advanced Technologies Division's compound libraries. Axys will receive an upfront payment and other payments upon the achievement of certain research and development milestones, according to the agreement. Specific targets and financial terms were not disclosed.